Michael S. Leapman

Michael S. Leapman is an Associate Professor of Urology and Assistant Professor in Chronic Disease Epidemiology at Yale University, with appointments at Yale School of Medicine, Yale Cancer Center, and West Haven Veterans Affairs Medical Center. He specializes in urologic oncology with clinical focus areas in prostate, bladder, kidney, and testicular cancers.

• Education:
  • BA in Neurobiology and Behavior from Cornell University (2005)
  • MD from University of Maryland School of Medicine (2009)
  • Residency and Fellowship at Mount Sinai Hospital and University of California San Francisco
  • MHS from Yale University (2022)

Dr. Leapman's research spans prostate cancer treatment optimization, active surveillance protocols, robotic surgery, focal therapy applications, and health disparities in genomic testing. His work addresses clinical outcomes, health services research, and cancer survivorship.

Recent publications examine radical prostatectomy outcomes, radiation therapy efficacy, automated surgical outcome analysis, and sociodemographic disparities in cancer care. Key themes include precision oncology, minimally invasive procedures, and prognostic biomarkers.

• Scientific Awards
  • John N. Forrest Jr. Prize for Mentorship (2022)
  • Best Poster Award (2016)
  • Merit Award (2015)
  • First Place Essay (2015)
  • Outstanding Abstract (2015)

Dr. Leapman leads clinical trials like SIMCAP (NCT: HIC ID 2000031290) and CAPTAIN (HIC ID 2000030487), focusing on metastatic prostate cancer treatment and localized prostate cancer ablation. His collaborations include prominent urologists and oncologists at Yale and national institutions.